New research finds that krill oil may significantly reduce fasting blood glucose.
Photo © iStockphoto.com
A new study published in the Journal of Nutritional Science1 found that krill oil from Rimfrost AS (Fosnavåg, Norway) significantly reduced fasting glucose in subjects, an important marker of cardiovascular risk. In the eight-week study investigating the effect krill oil and fish consumption had on markers of cardiovascular risk, 36 healthy subjects between the ages of 18 and 70 with fasting serum triacylglycerols between 1.3 and 4.0 mmol/l were divided into three groups: krill oil, lean and fatty fish, or placebo.
Results showed that supplementation with 4 g of krill oil per day significantly increased levels of omega-3 fatty acids EPA and DHA compared to control. The fish group also had significantly higher levels of omega-3s than control, though supplementation with krill resulted in significantly higher levels of EPA compared to eating fish. Additionally, the krill oil group was the only one to have significantly higher levels of omega-3 docosapentaenoic acid (DPA).
While both the krill oil and fish group had increases in plasma omega-3 levels, the krill oil group experience significant reduction in fasting glucose (from 5.6 down to 5.3 mmol/l), while the fish and control groups had increases in fasting glucose. Glucose levels are strongly associated with risk of cardiovascular disease, and a level of 5.6 mmol/l is considered pre-diabetic. “These interesting results will be investigated further in new clinical trials focusing on prevention of type 2 diabetes,” said Dr. Inge Bruheim, research manager at Rimfrost AS, in a press release.
1. Rundblad A et al. “Effects of krill oil and lean and fatty fish on cardiovascular risk markers: a randomised controlled trial.” Journal of Nutritional Science, vol. 7 (2018), no. 3
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.
Standardized valerian extract shows acute sleep benefits after one day, says recent study
December 10th 2024Results showed that after a single dose, people taking the Valerian extract experiences an acute benefit on sleep, namely a significant increase in actual sleep time compared to baseline.